Dizal's Sunvozertinib Licensing Deal with AstraZeneca Officially Takes Effect

Stock News

13 hours ago

Dizal Pharmaceutical Co.,Ltd. (688192.SH) has announced that its exclusive licensing agreement with AstraZeneca UK Limited for the global development and commercialization of Sunvozertinib has officially taken effect.

The company confirmed on July 14, 2026, that it had signed a licensing agreement granting AstraZeneca exclusive worldwide rights to develop and commercialize the drug. All conditions precedent outlined in the agreement have now been satisfied, with the deal becoming effective on August 31, 2026.

Under the terms of the agreement, AstraZeneca is set to launch Sunvozertinib commercially in the United States during the fourth quarter of this year. Dizal will receive a one-time, non-refundable upfront payment of $600 million from AstraZeneca, in addition to potential development milestone payments of up to $400 million and sales milestone payments of up to $500 million. Furthermore, Dizal is entitled to tiered royalties ranging from high-single-digit to low-double-digit percentages based on global net sales of Sunvozertinib.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/news/1176183367"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1176183367\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1176183367?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-01 08:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176183367","market":"sg","top_or_hot":-1,"title":"Dizal's Sunvozertinib Licensing Deal with AstraZeneca Officially Takes Effect","media":"Stock News","content":"<p><b>Dizal Pharmaceutical Co.,Ltd.</b> (688192.SH) has announced that its exclusive licensing agreement with AstraZeneca UK Limited for the global development and commercialization of Sunvozertinib has officially taken effect.<br><br>The company confirmed on July 14, 2026, that it had signed a licensing agreement granting AstraZeneca exclusive worldwide rights to develop and commercialize the drug. All conditions precedent outlined in the agreement have now been satisfied, with the deal becoming effective on August 31, 2026.<br><br>Under the terms of the agreement, AstraZeneca is set to launch Sunvozertinib commercially in the United States during the fourth quarter of this year. Dizal will receive a one-time, non-refundable upfront payment of $600 million from AstraZeneca, in addition to potential development milestone payments of up to $400 million and sales milestone payments of up to $500 million. Furthermore, Dizal is entitled to tiered royalties ranging from high-single-digit to low-double-digit percentages based on global net sales of Sunvozertinib.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dizal's Sunvozertinib Licensing Deal with AstraZeneca Officially Takes Effect</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDizal's Sunvozertinib Licensing Deal with AstraZeneca Officially Takes Effect\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-01 08:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Dizal Pharmaceutical Co.,Ltd.</b> (688192.SH) has announced that its exclusive licensing agreement with AstraZeneca UK Limited for the global development and commercialization of Sunvozertinib has officially taken effect.<br><br>The company confirmed on July 14, 2026, that it had signed a licensing agreement granting AstraZeneca exclusive worldwide rights to develop and commercialize the drug. All conditions precedent outlined in the agreement have now been satisfied, with the deal becoming effective on August 31, 2026.<br><br>Under the terms of the agreement, AstraZeneca is set to launch Sunvozertinib commercially in the United States during the fourth quarter of this year. Dizal will receive a one-time, non-refundable upfront payment of $600 million from AstraZeneca, in addition to potential development milestone payments of up to $400 million and sales milestone payments of up to $500 million. Furthermore, Dizal is entitled to tiered royalties ranging from high-single-digit to low-double-digit percentages based on global net sales of Sunvozertinib.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159938","symbol_name":"医药","start_time":0,"source_url":"","article_id":"1176183367","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176183367","pubTimestamp":1788223828,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Dizal Pharmaceutical Co.,Ltd. (688192.SH) has announced that its exclusive licensing agreement with AstraZeneca UK Limited for the global development and commercialization of Sunvozertinib has...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","688192":"迪哲医药-U","09939":"开拓药业-B","BK0239":"医药制造","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"Dizal 与阿斯利康的 Sunvozertinib 许可协议正式生效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"688192":1,"09939":1},"content_text":"Dizal Pharmaceutical Co.,Ltd. (688192.SH) has announced that its exclusive licensing agreement with AstraZeneca UK Limited for the global development and commercialization of Sunvozertinib has officially taken effect.The company confirmed on July 14, 2026, that it had signed a licensing agreement granting AstraZeneca exclusive worldwide rights to develop and commercialize the drug. All conditions precedent outlined in the agreement have now been satisfied, with the deal becoming effective on August 31, 2026.Under the terms of the agreement, AstraZeneca is set to launch Sunvozertinib commercially in the United States during the fourth quarter of this year. Dizal will receive a one-time, non-refundable upfront payment of $600 million from AstraZeneca, in addition to potential development milestone payments of up to $400 million and sales milestone payments of up to $500 million. Furthermore, Dizal is entitled to tiered royalties ranging from high-single-digit to low-double-digit percentages based on global net sales of Sunvozertinib.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}